AVANZANITE BIOSCIENCE PARTNERS WITH ADVICENNE TO COMMERCIALIZE SIBNAYAL® FOR THE TREATMENT OF RARE KIDNEY DISEASE IN GERMANY, AUSTRIA, SWITZERLAND AND GREECE
• Advicenne agreement further validates Avanzanite’s unique businessmodel and establishes it as the go-to commercialization partner formedicines treating rare diseases across Europe. • Avanzanite now transitioning to sales execution with the firstanticipated commercial launch in Germany mid 2023. AMSTERDAM, the Netherlands, February 28, 2023 – AvanzaniteBioscience B.V. (“Avanzanite” or the “Company”), a specialtypharmaceutical company offering […]
AVANZANITE BIOSCIENCE LAUNCHES NOVEL BUSINESS MODEL TO COMMERCIALIZE INNOVATIVE MEDICINES FOR RARE
AMSTERDAM, the Netherlands, Nov 15, 2022 – Today, Avanzanite Bioscience B.V. (“Avanzanite” or the “Company”) officially launches its commercial-stage enterprise, seeking to expand patient access to medicines for rare diseases in Europe while unlocking revenue and growth potential for emerging research-based biopharmaceutical originators. Avanzanite, a fully authorized distributor of medicinal products, partners with these biopharmaceutical collaborators through […]
